BHVN Stock Summary and Trading Ideas (Biohaven Ltd. Common Shares | NYSE:BHVN)

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.

As of September 30, 2026, BHVN stock price climbed to $13.35 with 1,324,579 million shares trading.

BHVN has a beta of 2.31, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.08 to the broad based SPY ETF.

BHVN has a market cap of $2.02 billion. This is considered a Mid Cap stock.

In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.

The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, VXF, IWO, IBB.

BHVN has underperformed the market in the last year with a return of -8.9%, while the SPY ETF gained +16.1%. In the last 3 month period, BHVN fell short of the market, returning -10.7%, while SPY returned +3.2%. However, in the most recent 2 weeks BHVN has outperformed the stock market by returning +8.2%, while SPY returned +0.9%.

BHVN support price is $12.58 and resistance is $14.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.